A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Procyon's Debt-to-EBITDA or its related term are showing as below:
PCYN's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.66 * Ranked among companies with meaningful Debt-to-EBITDA only.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Procyon Debt-to-EBITDA Related Terms
Procyon Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Procyon's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PCYN vs KAYS, YCBD, CBDY: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Procyon's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Procyon Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Procyon's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Procyon's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2024) EBITDA data.
Procyon (PCYN) has a Debt-to-EBITDA of 0.58 as of Jun. 2024. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Procyon.
Is Procyon's Debt-to-EBITDA too high?
Procyon's current Debt-to-EBITDA is 0.58. The Drug Manufacturers industry median Debt-to-EBITDA is 1.66. Procyon's value of 0.58 is 65.1% below this industry median. Overall, Procyon has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Procyon's Debt-to-EBITDA compare to KAYS and YCBD?
Procyon's Debt-to-EBITDA of 0.58 can be compared against companies in the Drug Manufacturers industry. The industry median Debt-to-EBITDA is 1.66. Procyon's value of 0.58 is 65.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.66, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Procyon's current Debt-to-EBITDA of 0.58 is 65.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Procyon. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Procyon's current Debt-to-EBITDA is 0.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Procyon stock overvalued right now?
Procyon (PCYN) has a current Debt-to-EBITDA of 0.58. The current Debt-to-EBITDA is 0.58 and 65.1% below the Drug Manufacturers industry median of 1.66. Procyon's overall GF Score™ is 48/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Procyon (PCYN), the current Debt-to-EBITDA is 0.58 as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Procyon Corp is a United-based company, through its subsidiary, it is engaged in developing and marketing proprietary medical products used to treat pressure ulcers, stasis ulcers, wounds, dermatitis, inflammation, and other skin problems. Its wound care products are sold through distributors to institutional customers such as hospitals, wound care clinics, skilled nursing facilities, home health agencies, and physicians and other healthcare practitioners. The firm's product lines are AMERX, AMERIGEL, and HELIX3 Bioactive Collagen. The skin and wound care products are marketed under the trademark AMERIGEL which contains the proprietary ingredient OAKIN which promotes wound healing and healthy skin. The corporation markets its products in the United States.
48GF Score
Get the complete analysis for PCYN
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PCYN has been successfully added to your 
